For cancer patients, medicines administered in clinical trials can help save or extend lives. But despite thousands of trials in the United States each

Triomics has filed a notice of an exempt offering of securities to raise $14,135,000.00 in New Equity Investment. Triomics has filed a notice of an exempt offering of securities to raise $14,135,000.00 in New Equity Investment.According to filings with the U.S. Securities and Exchange Commission, Triomics is raising $14,135,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Sarim Khan played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.About TriomicsTriomics combines the most advanced clinical trial tracking software with a global network of supersites and partners to deliver rapid, cost-effective, high quality clinical trials that pass even the most rigorous regulatory scrutiny. Triomics Harmony© is powering a host of next-generation applications of healthcare data and systems for advancing clinical research by harnessing the growing maturity of US healthcare on FHIR and addressing its current limitations, enabling us to empower healthcare organizations at any phase of their FHIR adoption journey.To learn more about Triomics, visit http://www.triomics.in/Contact:Sarim Khan, Chief Executive Officer707-227-9112https://www.linkedin.com/in/sarim-khan-triomics/SOURCE: http://www.intelligence360.ioCopyright (c) 2023 SI360 Inc. All rights reserved